Home » Authors » James Etheridge

Articles by James Etheridge

Neurotech Acquires Exclusive License From Amgen For CNTF

Jan. 16, 2002

By James Etheridge

Neurotech Acquires Exclusive License From Amgen For CNTF

Jan. 16, 2002

By James Etheridge

French Parliament Could Vote To Allow Therapeutic Cloning

Jan. 16, 2002

By James Etheridge

ExonHit Partners With IDEC To Develop Antibody Therapeutics

Jan. 9, 2002

By James Etheridge

PARIS - ExonHit Therapeutics SA and IDEC Pharmaceuticals Corp. signed a collaboration and research agreement aimed at discovering new antigen targets for antibody therapy, with a particular focus on prostate carcinoma.

ExonHit Partners With IDEC To Develop Antibody Therapeutics

Jan. 9, 2002

By James Etheridge

PARIS - ExonHit Therapeutics SA and IDEC Pharmaceuticals Corp. signed a collaboration and research agreement aimed at discovering new antigen targets for antibody therapy, with a particular focus on prostate carcinoma.

Crucell Unveils AdVac, Its New Genetic Vaccination Technology

June 6, 2001

By James Etheridge

Crucell Unveils AdVac, Its New Genetic Vaccination Technology

June 6, 2001

By James Etheridge

Transgene Financing Nets $54M; BioMérieux Stake Reaches 70%

May 30, 2001

By James Etheridge

Hybrigenics, Institut Curie Create Joint Cancer Research Facility

May 30, 2001

By James Etheridge

Neurotech Raises $30M Privately To Fund Work In Cell Therapies

May 30, 2001

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...